Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
The first personalized cancer vaccine reaches pivotal testing

The first personalized cancer vaccine reaches pivotal testing

New Capabilities

Moderna-Merck mRNA therapy shows durable five-year melanoma recurrence reduction as Phase 3 trials complete enrollment

January 21st, 2026: Moderna Stock Surges 15% on Five-Year Data

Overview

Cancer vaccines have promised to train the immune system against tumors for decades. None has delivered a durable, replicable benefit until now.

On January 20, 2026, Moderna and Merck reported that their personalized mRNA vaccine combined with Keytruda cut melanoma recurrence or death risk by 49% at five years in a Phase 2b trial of 157 patients. The result matched the three-year mark, suggesting a lasting rather than temporary benefit.

The announcement triggered a 15% surge in Moderna's stock, establishing the company as a leader in personalized cancer vaccines. With the Phase 3 melanoma trial (INTerpath-001) fully enrolled and the parallel lung cancer trial (INTerpath-002) now recruiting, regulatory submissions are expected by late 2026. If Phase 3 replicates the durability seen in Phase 2b, patients could access the first personalized cancer vaccine by 2027, validating mRNA beyond infectious disease.

Play on this story Voices Debate Predict

Key Indicators

49%
Recurrence Risk Reduction
Risk of melanoma recurrence or death reduced versus Keytruda alone at five years
75.3%
5-Year Recurrence-Free Survival
Combination therapy versus 55.6% for Keytruda monotherapy
34
Neoantigens Per Vaccine
Each dose custom-manufactured from patient's unique tumor mutations
1,089
Phase 3 Patients Enrolled
INTerpath-001 trial fully enrolled across 165+ sites in 25+ countries

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 5 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Timeline Five events from this story — drag them oldest to newest. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Stéphane Bancel
Stéphane Bancel
Positioning Moderna's cancer vaccine pipeline as core to post-pandemic strategy
 Dean Y. Li
Dean Y. Li
Overseeing Merck's post-Keytruda pipeline strategy

Organizations Involved

Moderna
Moderna
Biotechnology Company
Co-developer of mRNA-4157/V940 cancer vaccine

The company that proved mRNA vaccines could work at pandemic scale, now attempting to prove they work against cancer.
Merck & Co.
Merck & Co.
Pharmaceutical company
Co-developer and commercialization partner

The maker of Keytruda—the world's best-selling drug—seeking its successor before patent expiration.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Granted Breakthrough Therapy Designation

The agency whose regulatory decisions will determine when—and whether—the vaccine reaches patients.

Timeline

January 2016 January 2026

15 events Latest: January 21st, 2026 · 4 months ago Showing 8 of 15
Tap a bar to jump to that date

  1. Moderna Stock Surges 15% on Five-Year Data

    Latest Financial

    Moderna shares jump 15% following announcement of sustained 49% risk reduction, with analysts projecting potential approval by 2027.

  2. Five-Year Data: 49% Risk Reduction Holds

    Data Release

    Five-year follow-up confirms sustained 49% reduction in recurrence or death, with 75.3% recurrence-free survival versus 55.6% for Keytruda alone.

  3. Phase 3 Melanoma Trial Fully Enrolled

    Clinical Trial

    INTerpath-001 completes enrollment of 1,089 patients, setting up interim data readout and potential regulatory submission.

  4. Bancel Frames Cancer Vaccine as Post-Pandemic Pivot

    Strategic

    At J.P. Morgan Healthcare Conference, Moderna CEO describes 2026 pipeline as 'full of catalysts' with cancer vaccine central to company's oncology transformation.

  5. Second Lung Cancer Phase 3 Trial Initiates

    Clinical Trial

    INTerpath-003 begins enrolling patients receiving mRNA-4157 as adjuvant therapy following neoadjuvant Keytruda and chemotherapy in resected NSCLC.

  6. Three-Year Data Confirms Durability

    Data Release

    Three-year follow-up shows 49% risk reduction maintained, suggesting durable immune reprogramming rather than temporary benefit.

  7. Lung Cancer Phase 3 INTerpath-002 Begins

    Clinical Trial

    Phase 3 trial initiates for adjuvant treatment of resected Stage II-IIIB non-small cell lung cancer, targeting disease-free survival endpoint.

  8. Phase 3 INTerpath-001 Initiates

    Clinical Trial

    Global Phase 3 trial begins, targeting 1,089 patients across 165+ sites in 25+ countries.

  9. FDA Grants Breakthrough Therapy Designation

    Regulatory

    FDA designates mRNA-4157 plus pembrolizumab as Breakthrough Therapy for adjuvant treatment of high-risk melanoma.

  10. Initial Results: 44% Risk Reduction

    Data Release

    Two-year follow-up data shows 44% reduction in recurrence or death risk, triggering FDA Breakthrough Therapy Designation application.

  11. Merck Exercises $250M Option

    Financial

    Merck pays $250 million to exercise its option for joint development and commercialization, splitting future costs and profits 50-50.

  12. KEYNOTE-942 Trial Begins

    Clinical Trial

    Phase 2b trial initiates enrollment, randomizing patients 2:1 to mRNA-4157 plus Keytruda versus Keytruda alone.

  13. Partnership Expands to Shared Antigens

    Partnership

    Moderna and Merck expand collaboration to include shared antigen mRNA cancer vaccines, including KRAS-targeting mRNA-5671.

  14. mRNA-4157 Development Begins

    Development

    Moderna initiates development of mRNA-4157, a personalized neoantigen therapy encoding up to 34 tumor-specific mutations.

  15. Moderna-Merck Partnership Begins

    Partnership

    Moderna and Merck form initial collaboration on personalized mRNA cancer vaccines, with Merck investing $125 million in Moderna equity.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

April 2010 - November 2014

Provenge (Sipuleucel-T) Approval and Dendreon Collapse (2010-2014)

The FDA approved Provenge, the first therapeutic cancer vaccine, for metastatic prostate cancer in 2010. Developed by Dendreon, it extended median survival by 4.1 months and was priced at $93,000 per treatment course. Despite the breakthrough, Dendreon filed for bankruptcy in 2014.

Then

Reimbursement confusion, complex three-week manufacturing process, and competition from simpler oral drugs limited adoption to a fraction of eligible patients.

Now

Provenge survives under new ownership, but the failure chilled cancer vaccine investment for years. It proved personalized cell therapy could win FDA approval—but commercial success requires more than clinical efficacy.

Why this matters now

The Moderna-Merck vaccine faces similar manufacturing complexity—each dose custom-made for each patient. The partnership structure (two large companies sharing costs) and simpler mRNA manufacturing may avoid Dendreon's fate, but the precedent looms.

2011 - Present

Checkpoint Inhibitor Revolution (2011-Present)

Ipilimumab's 2011 FDA approval for melanoma launched the checkpoint inhibitor era. Keytruda followed in 2014, eventually becoming the world's best-selling drug at $29.5 billion annually. Five-year melanoma survival rates jumped from 15-20% to 34-52% for advanced disease.

Then

Checkpoint inhibitors transformed melanoma from a death sentence to a manageable disease for many patients, though response rates plateau around 40-50%.

Now

Keytruda's 2028 patent expiration creates both urgency and opportunity for Merck—the mRNA vaccine could extend Keytruda's relevance and create a new combination standard of care.

Why this matters now

The mRNA vaccine builds on rather than replaces checkpoint inhibitors—it provides immune targeting while Keytruda removes immune brakes. Success would represent the next evolution, not a replacement, of immuno-oncology.

December 2020 - December 2021

COVID-19 mRNA Vaccine Validation (2020-2021)

Moderna's mRNA-1273 and BioNTech/Pfizer's BNT162b2 became the first mRNA vaccines approved for human use, delivering in under a year what typically takes a decade. Billions of doses administered proved the technology safe and manufacturable at scale.

Then

Moderna's market cap briefly exceeded $150 billion. The company gained manufacturing expertise, regulatory credibility, and billions in revenue.

Now

COVID success validated mRNA as a platform but left an existential question: could the technology work beyond infectious disease? Cancer is the proving ground.

Why this matters now

The pandemic built the infrastructure, expertise, and investor confidence now being deployed against cancer. But cancer vaccines require personalization that COVID vaccines did not—a harder manufacturing and regulatory challenge.

Sources

(17)
+11
BioSpace PackGene Biotech Euronews The Lancet Merck ClinicalTrials.gov American Cancer Society PubMed StockTwits PharmExec FinancialContent pharmaphorum Cancer Health BioSpace Merck Merck Merck